The comparative in-vitro activity of CP-99219, a new quinolone, against Haemophilus influenzae (150 isolates), Moraxella catarrhalis (100), Streptococcus pneumoniae (80) and Group A /Nhaemolytic streptococci (40) was determined using an agar dilution technique. CP-99219 was the most active compound tested against M. catarrhalis (MIC» = 0.015 mg/L, MIC* = 0.03 mg/L). Ceftriaxone, CP-99219 and ciprofloxacin were the three most active agents tested against H. influenzae. CP-99219 showed good activity, 16-fold greater than that of ciprofloxacin, against S. pneumoniae (MIC» = 0.12 mg/L; MIC« = 0.25 mg/L) and was also active against Group A streptococci. Clinical studies regarding the use of CP-99219 in respiratory tract infections seem indicated.
Introduction
Fluoroquinolones are used extensively to treat a wide variety of infections. They are sometimes used to treat respiratory tract infections but, in general, have comparatively low activity against Streptococcus pneumoniae. CP-99219 is a novel fluoroquinolone reported to have enhanced activity compared with ciprofloxacin against Gram-positive bacteria (Eliopoulos, et al., 1993; Gooding & Jones, 1993; Neu & Chin, 1994) . Our study compared the in-vitro activity of CP-99219 with that of ciprofloxacin, macrolides and /Mactam antimicrobial agents against a range of respiratory pathogens.
Materials and Methods Bacteria
All bacteria studied were recent clinical isolates, and included Haemophilus influenzae (n = 150), Moraxella catarrhalis (100), S. pneumoniae (80) and Group A streptococci (40) . The H. influenzae isolates studied included ampicillin-sensitive strains (50), /?-lactamase producing strains (50) and ampicillin-resistant, non-/?-lactamase producing strains (50) (MIC of ampicillin > 1 mg/L). The isolates had been stored at -70°C.
Antimicrobial agents
Antimicrobial agents used were CP-99219 and azithromycin, (Pfizer Ltd, Sandwich, UK), ciprofloxacin, erythromycin, tetracycline, amoxycillin, penicillin G, cephalothin, ceftriaxone and cefuroxime (Sigma Chemical Co., St Louis, MO, USA),
amoxycillin-clavulanic acid (Beecham Research Laboratories, UK) and ampicillinsulbactam (Leo Laboratories Ltd, Princes Risborough, UK).
Sensitivity testing
A standard agar dilution technique was performed using a multipoint inoculator (Denley Instruments) and a final inoculum of 10*cfu. Iso-Sensitest Agar (Oxoid) was used for susceptibility studies on M. catarrhalis, S. pneumoniae and Group A streptococci; the agar was supplemented with 5% lysed blood for S. pneumoniae and Group A streptococci. Diagnostic Sensitivity Testing (DST) agar (Oxoid) was used for susceptibility studies on H. influenzae. In general the DST agar was supplemented with 0.25% lysed blood and 10 mg/L nicotinamide adenine dinucleotide (NAD) (Merk, Lutterworth, UK); plates for macrolide sensitivity testing contained 5% lysed blood and 10 mg/L NAD to enable better aerobic growth.
All plates were incubated for 18 h at 35°C before MICs were read. Plates for susceptibility testing of M. catarrhalis, S. pneumoniae and Group A streptococci were incubated aerobically. Plates for determining the susceptibility of H. influenzae to erythromycin and azithromycin were also incubated aerobically, but the remainder were placed in air with 5% CO 2 .
Results
The comparative in-vitro activity of the agents, tested against H. influenzae are shown in Table I . The two quinolones showed a unimodal distribution of activity against irrespective of whether they were ampicillin-sensitive, ampicillin resistant /Mactamase producing strains or ampicillin resistant non-/?-lactamase producing strains. The activity of CP-99219 and ciprofloxacin was high and similar. The macrolides also showed a unimodal distribution although azithromycin was more active than erythromycin. Amoxycillin-clavulanic acid and ampicillin-sulbactam had similar activity to amoxycillin against ampicillin susceptible and ampicillin-resistant non-/?-lactamase producing strains. Tetracycline had uniform activity against the ampicillin-susceptible and ampicillin-resistant strains; 6% of strains were resistant. Table II shows the comparative in-vitro activity of the agents tested against M. catarrhalis, S. pneumoniae and Group A streptococci. Both CP-99219 and ciprofloxacin had excellent activity against M. catarrhalis with all strains being inhibited by < 0.06 mg/L of either compound. The macrolides also had good activity against M. catarrhalis, although azithromycin (mode MIC = 0.03 mg/L) was about four times as active as erythromycin. Cephalothin and cefuroxime had similar activity against both H. influenzae and M. catarrhalis, but ceftriaxone was considerably less active against M. catarrhalis than against H. influenzae (MICM and MIC*) of 0.12 and 0.5 mg/L compared with <0.015 and 0.12 mg/L respectively). All isolates of M. cararrhalis were susceptible to < 0.5 mg/L tetracycline, and co-trimoxazole also had good activity against M. catarrhalis with all isolates being inhibited by ^4 mg/L of this compound.
There was a marked difference in activity between CP-99219 and ciprofloxacin against 5. pneumoniae. All isolates were inhibited by <0.5mg/L CP-99219 compared with 8 mg/L ciprofloxacin (the mode MICs were 0.12 and 2 mg/L, respectively). The macrolides had similar activity against S. pneumoniae; both erythromycin and azithromycin had a mode MIC of 0.06 mg/L, although 17% of strains were macrolide-resistant (mode MIC>2mg/L). Penicillin G, amoxycillin, ccfuroxime and ceftriaxone showed uniformly high activity against penicillin-sensitive strains of S. pneumoniae; all four compounds had a mode MIC of 0.03 mg/L. Four strains had decreased susceptibility to penicillin (MIC 0.12-2 mg/L) and cross-resistance was shown with all /?-lactam agents. Cephalothin had overall lower activity than the other /?-lactam antibiotics. Eighty two per cent of isolates were inhibited by ^ 1 mg/L tetracycline; only one isolate required > 4 mg/L tetracycline for inhibition.
CP-99219 was approximately four times as active as ciprofloxacin against group Â -haemolytic streptococci; all 40 isolates were inhibited by ^0.5 mg/L CP-99219 (mode MIC = 0.12 mg/L). Forty percent of strains had a tetracycline MIC of ^8 mg/L. Approximately 8% of strains were resistant to erythromycin and azithromycin.
Discussion
Our study showed CP-99219 to have good in-vitro activity, comparable with that of ciprofloxacin, against H. influenzae and M. catarrhalis. This is in agreement with the findings of Gooding & Jones (1993) and Neu & Chin (1994) , although our study examined a larger number of isolates than the other studies. We found CP-99219 to have greater in-vitro activity than ciprofloxacin against S. pneumoniae and group A streptococci. Gooding & Jones (1993) , Eliopoulos et al. (1993) and Neu & Chin (1994) reported similar findings. Klugman & Wasas (1994) ; Olsson-Liljequist, Hoffman & Hedlund (1994) and Pankuch, Jacobs & Appelbaum (1994) also found CP-99219 to have superior activity compared with ciprofloxacin against S. pneumoniae and, in addition, found its activity to be uninfluenced by the degree of penicillin susceptibility of the pneumococci. Eliopoulos et al. (1993) , Klugman & Wasas (1994) , Neu & Chin (1994) and Pankuch et al. (1994) all found CP-99219 to be more active than sparfloxacin against S. pneumoniae.
In addition to showing good activity against H. influenzae, M. catarrhalis, S. pneumoniae and group A streptococci, Felmingham et al. (1994) found CP-99219 to be highly active in vitro against Legionella spp. and Chlamydia pneumoniae. Wise, Andrews & Brenwald (1994) confirmed the high activity of CP-99219 against C. pneumoniae (MIC*, = 0.06 mg/L). Toxicity and pharmacokinetic studies relating to use of CP-99219 in animals have been performed, and studies in humans are in progress. Assuming that CP-99219 proves to be non-toxic in humans it is likely to be a useful agent for treating community acquired respiratory tract infections, especially those occurring in penicillin allergic patients.
